Osteosarcoma is a type of bone cancer that originates in the cells that form an individual's bones. In rare cases, it may ...

A new review highlights SETDB1 as a key player in osteosarcoma, promoting tumor growth, immune evasion and therapy resistance ...

These funds are earmarked for finalizing the OST-HER2 osteosarcoma trial payments, manufacturing for FDA approval, and other operational costs, including the commercialization of the product.

OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar ...

“Importantly, this agreement eliminates certain near-term milestone payment obligations related to OST-HER2 in osteosarcoma, projected sales milestone payments, and significantly reduces our ...

But for some types of bone cancer, younger people have a higher risk. Osteosarcoma is more common in adolescents (10 to 19 years). It seems to be linked to the growth of the bones during puberty.

LOUISVILLE, Kentucky (WLKY) — Manual senior Davis Randle was able to finally join his Crimson teammates on the court Wednesday night after battling cancer. Randle was diagnosed with Osteosarcoma ...

About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.

Pain has been a part of my life throughout my childhood. At the age of 12 years, I was diagnosed with metastatic osteosarcoma ...

A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.” ...